1. Elraglusib Induces Cytotoxicity via Direct Microtubule Destabilization Independently of GSK3 Inhibition.
- Author
-
Coats JT, Li S, Tanaka TU, Tauro S, Sutherland C, and Saurin AT
- Subjects
- Humans, Cell Line, Tumor, Antineoplastic Agents pharmacology, Antineoplastic Agents adverse effects, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors adverse effects, Microtubules drug effects, Microtubules metabolism, Glycogen Synthase Kinase 3 antagonists & inhibitors, Glycogen Synthase Kinase 3 metabolism
- Abstract
Significance: Elraglusib was designed as a GSK3 inhibitor and is currently in clinical trials for several cancers. We show conclusively that the target of elraglusib that leads to cytotoxicity is MTs and not GSK3. This has significant implications for ongoing clinical trials of the compound and will help in understanding off-target side effects, inform future clinical trial design, and facilitate the development of biomarkers to predict response., (©2024 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF